An interventional study of stSCS+Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline) and Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline) in Central Post-Stroke Pain, sponsored by Nanchong Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Nanchong Central Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies in Pain with a site in China — 66 open to participants now, 72 under way, 2 of them phase 3. Pain · China.
Among the 247 studies in Pain with a site in China, this one is the 135th largest by planned enrollment of the 212 interventional ones that give a count, is one of 19 that started in 2024, is one of 117 with no phase, reaches primary completion later than 70 of the 71 other live ones, and was the 233rd registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →66 of the 247 studies in Pain with a site in China are open now. Recruiting first, the newest first:
Yi Duan · Sites in China
Ages 18–75
Novartis Pharmaceuticals · Sites in China
Ages 18+
Yingyong Zhou,MD,PhD · Sites in China
Ages 18+
Haisco Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Lijiang Lv · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 27 · Phase 3 26 · Phase 4 30
First in 1992; this study’s year is marked. 19 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 120 across the 212 interventional studies, 169 across the 34 observational. Of the 122 that completed or were terminated, 17 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 247 have an industry lead sponsor. The 10 most frequent:
Nanchong Central Hospital is the lead sponsor of 21 studies on the registry; 14 are open to participants now.
Nanchong Central Hospital has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
30 of the studies in Pain with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07872826Phase 3The Third Xiangya Hospital of Central South UniversityA Clinical Trial Evaluating the Efficacy and Safety of Local Infiltration of RF16001 for Injection for Analgesia After Total Hip Arthroplasty in China | 2027-06-30 |
| NCT07533786Haisco Pharmaceutical Group Co., Ltd.A Clinical Trial Evaluating the Efficacy and Safety of HSK55718 in Patients for Postoperative Pain Treatment in Abdominal Surgery | 2026-11-22 |
| NCT06553495Jie ChenA Comparative Analysis of Intertransverse Nerve Block and Paravertebral Nerve Block in Endoscopic Hepatectomy | 2026-11-30 |
| NCT07947511Dove Medical Press LtdOral-Challenge Study: Steady-State High-ORP Water/Gel Relieves AITC- and Capsaicin-Induced Oral Pain in Healthy Volunteers | 2026-12-22 |
| NCT07557823Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTranscutaneous Auricular Vagus Nerve Stimulation Combined With Cervical Epidural Injection for Cervical Radiculopathy | 2026-12-30 |
Add all 30 to your calendar (.ics) → With an account.
Among the 247 studies in Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the short-term analgesic efficacy of stSCS combined with pharmacotherapy compared with pharmacotherapy alone in patients with CPSP, measured by Numerical Rating Scale (NRS) score immediately after treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received conventional pharmacotherapy alone without any form of SCS.
Drug: Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)
Patients received stSCS in addition to conventional pharmacotherapy.
Procedure: stSCS+Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)
Patients received stSCS in addition to conventional pharmacotherapy. stSCS Procedure: Under digital subtraction angiography (DSA) guidance, a temporary electrode (typically an 8-contact electrode) was percutaneously placed into the corresponding spinal cord segment (cervical C2-C4 or thoracic T8-T10, depending on the pain distribution area). The electrode was connected to an external stimulator to deliver continuous stimulation for 7-14 days. Stimulation parameters were as follows: frequency 40-60 Hz (conventional mode) or BurstDR mode, pulse width 210-450 μs, and amplitude individually adjusted based on the patient's sensory threshold (targeting a comfortable paresthesia covering the painful area). After the test period, the electrode was removed without a second-stage implantation. Postoperatively, patients continued receiving baseline pharmacotherapy, which could be reduced as appropriate.
Patients received conventional pharmacotherapy alone without any form of SCS. The medication regimen followed the 2025 International Association for the Study of Pain (IASP) recommendations, with gabapentin (starting at 300 mg/d, gradually titrated to 900-1800 mg/d based on tolerability, administered in 2-3 divided doses) or pregabalin (starting at 75 mg/d, gradually titrated to 150-300 mg/d in 2-3 divided doses) as the foundation, and could be combined with duloxetine (60-120 mg/d) or amitriptyline (25-75 mg at bedtime). Drug doses were individually adjusted by the attending physician according to patient response and tolerability.
Numerical Rating Scale (NRS) score
The primary outcome was pain intensity measured by the NRS(0-10) recorded at baseline, immediately after stimulation termination (study group)/at the corresponding time point after treatment (control group), and at 1, 3, and 6 months post-treatment. The proportions of patients with an NRS reduction of ≥30% and ≥50% from baseline were also recorded, with the latter defined as treatment response. NRS ranges from 0 (no pain) to 10 (worst possible pain). Higher scores indicate worse pain.
Time frame: Six months
Change in Sleep Quality assessed by the Pittsburgh Sleep Quality Index (PSQI)
The PSQI total score ranges from 0 to 21. Higher scores indicate worse sleep quality
Time frame: 6 months
Change in Physical Health assessed by the 36-Item Short Form Health Survey Physical Component Summary (SF-36 PCS)
The SF-36 PCS score ranges from 0 to 100. Higher scores indicate better physical health
Time frame: 6 months
Change in Mental Health assessed by the 36-Item Short Form Health Survey Mental Component Summary (SF-36 MCS)
The SF-36 MCS score ranges from 0 to 100. Higher scores indicate better mental health
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Aug 2029, 67 months after the start.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 67 months is above that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Aug 2029 and completion Aug 2026 → Aug 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanchong Central Hospital